

PET/CT in endocarditis: Kouijzer and colleagues provide an overview of ^{18}F -FDG PET/CT as the diagnostic imaging modality of choice in patients with infectious endocarditis, with an emphasis on detection and localization of septic foci. **Page 1045**

Absorbed dose and PFS after RIT: Dewaraja and colleagues identify patient-specific dosimetric and nondosimetric factors predicting progression-free survival in non-Hodgkin lymphoma after ^{131}I -tositumomab radioimmunotherapy. . . **Page 1047**

NaF PET outside the prostate: Hillner and colleagues report on National Oncologic PET Registry data assessing the impact of ^{18}F -sodium fluoride PET on intended management of Medicare patients with suspected or known osseous metastasis. **Page 1054**

Surveillance PET/CT and survival: Antoniou and colleagues assess the added value of follow-up ^{18}F -FDG PET/CT in clinical assessment and prediction of survival outcomes in patients with biopsy-proven lung cancer. **Page 1062**

Optimal PET/CT imaging during RT for NSCLC: Everitt and colleagues use serial ^{18}F -FDG and ^{18}F -FLT PET/CT to observe cellular metabolism and proliferation as signs of early response in patients with non-small cell lung cancer during chemoradiation therapy. . . **Page 1069**

^{18}F -FLT PET in acute hematotoxicity: Leimgruber and colleagues investigate the potential of ^{18}F -FLT PET to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens. **Page 1075**

PET and neoadjuvant erlotinib therapy: van Gool and colleagues evaluate the timing of metabolic response monitoring with ^{18}F -FDG PET/CT early in erlotinib treatment in patients with early-stage non-small cell lung cancer. **Page 1081**

^{89}Zr -bevacizumab in NETs: van Asselt and colleagues explore the effect of everolimus on tumor uptake of the radiolabeled vascular endothelial growth factor A antibody bevacizumab using PET in patients with advanced neuroendocrine tumors. **Page 1087**

PET/CT in infectious endocarditis: Kestler and colleagues study the clinical and practical impacts of systematic PET/CT imaging, from vertex to mid thigh, on diagnosis of infectious embolisms in patients with infectious endocarditis. **Page 1093**

SPECT-MR and PET in pediatric epilepsy: Perissinotti and colleagues compare the results

of video electroencephalography, brain MR, interictal SPECT, ictal SPECT, and subtraction ictal SPECT coregistered to MR imaging with those of interictal ^{18}F -FDG PET in pediatric patients with epilepsy. **Page 1099**

BBB P-gp activity in AD: Deo and colleagues elucidate relationships between reductions in regional cerebral blood flow and blood-brain barrier P-glycoprotein activity in patients with mild Alzheimer disease and cognitively normal participants. **Page 1106**

PET and MR in MS: Colasanti and colleagues use ^{18}F -PBR111 PET and MR imaging to measure relative binding in the lesional, perilesional, and surrounding normal-appearing white matter of patients with multiple sclerosis, as a potential index of innate immune response. . . **Page 1112**

^{18}F -FPEB radiation dosimetry: Kessler and colleagues report on human radiation dosimetry and associated recommendations with this potent and specific PET radioligand for the metabotropic glutamate receptor subtype 5. **Page 1119**

Quantification of ^{18}F -fluoride uptake: Raijmakers and colleagues assess the performance of various clinically useful simplified methods for ^{18}F -fluoride PET measurement of bone metabolism and bone blood flow and compare these with full kinetic analysis. **Page 1122**

Exocrine pancreas stress test: O and colleagues detail the development of a noninvasive imaging test of pancreatic exocrine function using ^{11}C -acetate PET imaging before and after intravenous secretin stimulation. . . **Page 1128**

PET drug regulatory requirements: Schwarz and colleagues provide an educational view of U.S. Food and Drug Administration oversight of PET drug production for clinical and clinical research uses, including a review of compliance, inspection, and reporting regulations. . . **Page 1132**

PET and breast microcalcifications: Wilson and colleagues offer preliminary evidence that ^{18}F -NaF PET imaging can detect breast cancer by targeting the hydroxyapatite lattice within the tumor microenvironment with high specificity and soft-tissue contrast-to-background ratio while differentiating tumors from inflammation. **Page 1138**

Optimizing ^{11}C -acetate tumor imaging: Lewis and colleagues measure uptake and metabolism of ^{11}C -acetate on PET in mouse prostate and lung cancer models to investigate the time course of complete incorporation into tumor metabolites. **Page 1144**

In vivo labeling of albumin: Niu and colleagues describe the development of an albumin labeling method to allow PET imaging of cardiac function after myocardial infarction and of vascular leakage and increased permeability in inflammatory diseases and malignant tumors. **Page 1150**

Fibrin-targeting PET probes: Blasi and colleagues provide details on 4 new ^{64}Cu - or Al^{18}F -labeled PET probes based on fibrin-specific peptides and suitable for in vivo imaging of thrombus. **Page 1157**

^{18}F -labeled D_2/D_3 receptor agonist: Finnema and colleagues review their research in nonhuman primates with ^{18}F -MCL-524 PET and discuss the tracer's suitability for clinical quantification of D_2/D_3 receptor binding. **Page 1164**

$\alpha_2\text{C}$ -adrenoceptor PET tracer: Arponen and colleagues report on the development and pre-clinical evaluation of a PET tracer for $\alpha_2\text{C}$ adrenoceptor imaging and highlight its potential in neuropsychiatric disorders. **Page 1171**

^{18}F -DEG-VS-NT synthesis: Wu and colleagues detail a simple and efficient method for ^{18}F labeling of a thiolated neurotensin peptide for neurotensin receptor-targeted imaging. **Page 1178**

κ -opioid antagonist tracer: Zheng and colleagues review their experience in developing the selective κ -opioid receptor ^{11}C -LY2459989 as a PET radioligand and characterize its imaging performance in nonhuman primates. **Page 1185**

^{18}F -EF5 hypoxia imaging: Chitneni and colleagues look at tumor uptake of this radiolabeled PET tracer and binding of unlabeled tracer and the potential for combining them in assessment of hypoxia at both macroscopic and micro-regional levels. **Page 1192**

Dedicated breast PET scanner: Miyake and colleagues evaluate the performance characteristics of a newly developed dedicated breast PET scanner, using National Electrical Manufacturers Association NU 4-2008 standards. . . **Page 1198**

Engineered antibodies to improve PET: Swiercz and colleagues describe preclinical studies on a $^{124}\text{I}/^{125}\text{I}$ -labeled, antibody-based inhibitor of the FcRn receptor with potential for resolving challenges in antibody-based PET imaging associated with long half-lives. **Page 1204**

Diversification in $^{99\text{m}}\text{Tc}$ supply chain: Cutler and Schwarz discuss current global issues in availability of $^{99\text{m}}\text{Tc}$ and highlight progress in new production facilities, novel methods for production of ^{99}Mo , and innovative generator elution systems. **Page 1208**